Share

October 2017; 7 (5) Case

Chronic diphenhydramine abuse and withdrawal

A diagnostic challenge

Jagroop S. Saran, Richard L. Barbano, Rachel Schult, Timothy J. Wiegand, Olga Selioutski
First published September 14, 2016, DOI: https://doi.org/10.1212/CPJ.0000000000000304
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
528

Share

Article Information

vol. 7 no. 5 439-441
DOI: 
https://doi.org/10.1212/CPJ.0000000000000304
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received June 15, 2016
  • Accepted August 10, 2016
  • First Published September 14, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Jagroop S. Saran, MD,
    2. Richard L. Barbano, MD, PhD,
    3. Rachel Schult, PharmD,
    4. Timothy J. Wiegand, MD and
    5. Olga Selioutski, DO
  1. Jagroop S. Saran, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Richard L. Barbano, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Neurotoxin Association, non-commercial entity: I received travel expenses for workshop presentation. Jagellonian University, Poland: academic institution: I received travel honoraria for lectures/participation in conference

    Editorial Boards:

    1. Neurology Clinical Practice, Associate editor, 2011- present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I receive stock equity from Visual Dx as Neurology Section Editor

    Clinical procedures or imaging studies:

    1. University of Rochester, botulinum toxin injections, 30% effort, since 1994

    Research Support, Commercial Entities:

    1. 1. Vaccinex 2.Biotie

    Research Support, Government Entities:

    1. NIH, NINDS, ORDR: Dystonia Coalition Projects, Site PI Stock/Stock Options, Medical Equipment & Materials: VisualDx, 2014-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Expert witness in legal proceedings including malpractice, but NOT involving commercial entities

  3. Rachel Schult, PharmD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Timothy J. Wiegand, MD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I am an Associate Editor of the Encyclopedia of Toxicology, 3rd Edition. compensation related to editorial position --2012-14.

    Patents:

    1. NONE

    Publishing Royalties:

    1. UpToDate -Clinical Management of Mushroom Poisoning & Mushroom Poisoning annual royalties.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Research Abuse Diversion and Addiction Related Surveillance (RADARS) consultant.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Olga Selioutski, DO
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Presentations on OMED/ AOA and ABONP conferences. I received compensation for travel, hotel stay and honoraria for presentation

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Primary investigator for industry sponsored clinical trials supported by SAGE Therapeutics; Sepracor/Sunovion; Bial; Upsher-Smith companies.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Primary investigator for industry sponsored clinical trials supported by SAGE Therapeutics; Sepracor/Sunovion; Bial; Upsher-Smith companies.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Adjunct faculty at Genesee Community College Polysomnographic Technology Program since 01/15

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Departments of Anesthesiology (JSS), Neurology (RLB, OS), and Emergency Medicine (RS, TJW), University of Rochester School of Medicine and Dentistry; and Department of Pharmacy (RS), University of Rochester Medical Center, NY.
  1. Correspondence to:
    Jagroop_Saran{at}URMC.rochester.edu
View Full Text

Article usage

Article usage: September 2016 to April 2022

AbstractFullPdfSource
Sep 2016104014Highwire
Oct 201613406Highwire
Nov 20167301Highwire
Dec 20162704Highwire
Jan 20174504Highwire
Feb 20173601Highwire
Mar 20174201Highwire
Apr 20175104Highwire
May 20173602Highwire
Jun 20174802Highwire
Jul 20178705Highwire
Aug 20175800Highwire
Sep 20174501Highwire
Oct 20172551214Highwire
Nov 20173748246Highwire
Dec 201722036568Highwire
Jan 2018329916Highwire
Feb 2018186511Highwire
Mar 2018160320Highwire
Apr 2018192425Highwire
May 2018187125Highwire
Jun 2018202417Highwire
Jul 2018205312Highwire
Aug 20184071113Highwire
Sep 2018508105Highwire
Oct 2018562102Highwire
Nov 201848144Highwire
Dec 201855424Highwire
Jan 201955204Highwire
Feb 2019416614Highwire
Mar 2019371717Highwire
Apr 2019330714Highwire
May 2019338423Highwire
Jun 2019274324Highwire
Jul 2019254225Highwire
Aug 2019182323Highwire
Sep 20198521Highwire
Oct 20198737Highwire
Nov 20196415Highwire
Dec 20196822Highwire
Jan 20202903Highwire
Feb 20208816Highwire
Mar 20205501Highwire
Apr 20206600Highwire
May 20204800Highwire
Jun 20204700Highwire
Jul 20205700Highwire
Aug 20206921Highwire
Sep 202011900Highwire
Oct 202011012Highwire
Nov 202015912Highwire
Dec 202012111Highwire
Jan 202116312Highwire
Feb 202121223Highwire
Mar 202121004Highwire
Apr 202119801Highwire
May 202118900Highwire
Jun 202115511Highwire
Jul 202113841Highwire
Aug 202113753Highwire
Sep 202111800Highwire
Oct 202111745Highwire
Nov 202110620Highwire
Dec 20218411Highwire
Jan 20226901Highwire
Feb 202211502Highwire
Mar 202211420Highwire
Apr 20228142Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me